Andrew Berens

Stock Analyst at Leerink Partners

(1.17)
# 1971
Out of 5,372 analysts
222
Total ratings
51.49%
Success rate
2.01%
Average return
40 Stocks
Name Action PT Current % Upside Ratings Updated
ARVN Arvinas
Downgrades: Market Perform
10 9
7.63 17.96% 6 Jun 2, 2025
CMPX Compass Therapeutics
Upgrades: Outperform
4 6
2.31 159.74% 3 Apr 2, 2025
ELEV Elevation Oncology
Downgrades: Market Perform
9 1
n/a n/a 5 Mar 21, 2025
OKUR OnKure Therapeutics
Initiates Coverage On: Outperform
33
2.52 1209.52% 1 Dec 5, 2024
ZYME Zymeworks
Upgrades: Outperform
10 25
12.13 106.1% 10 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
74 96
108.03 -11.14% 1 Oct 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
60 56
34.54 62.13% 11 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
5 3
n/a n/a 5 Aug 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
29
11.92 143.29% 1 Jul 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Market Perform
50 97
128.22 -24.35% 24 May 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
69 110
76.33 44.11% 1 Apr 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
78
69.47 12.28% 12 Dec 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
78 58
n/a n/a 7 Nov 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
13 10
n/a n/a 2 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 48
52.52 -8.61% 5 Apr 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30
n/a n/a 11 Feb 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
162 141
n/a n/a 19 Feb 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
236 300
n/a n/a 11 Jan 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
18 20
7.58 163.85% 4 Jan 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
37 28
11.39 145.83% 3 Dec 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
78 79
71.33 10.75% 12 Nov 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
42 27
1.43 1788.11% 7 Nov 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 4 Oct 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 30
1.34 2138.81% 4 Aug 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
69
n/a n/a 4 Aug 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
101 76
n/a n/a 6 Jun 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
25 23
n/a n/a 5 May 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
36 25
8.53 193.08% 3 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
6.09 556.81% 1 Nov 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
n/a n/a 1 Nov 1, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
67
1.51 4337.09% 1 Oct 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
20
4.64 331.03% 1 Oct 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
25
4.86 414.4% 1 Sep 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
12 16
n/a n/a 5 May 7, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
4 3
n/a n/a 6 Nov 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Overweight
2000
n/a n/a 2 Sep 7, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
156 146
n/a n/a 3 Mar 1, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
102 18
n/a n/a 2 Sep 22, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
75 50
n/a n/a 5 Sep 22, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
16 8
8.45 -5.33% 7 Jul 14, 2017